Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb

Share this content:
Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb
Out-of-Pocket Costs Similar for Infliximab, Infliximab-Dyyb

WEDNESDAY, Sept. 5, 2018 (HealthDay News) -- Under Medicare Part D, out-of-pocket costs are similar for infliximab and its biosimilar infliximab-dyyb, according to a research letter published in the Sept. 4 issue of the Journal of the American Medical Association.

Jinoos Yazdany, M.D., M.P.H., from the University of California in San Francisco, and colleagues calculated the mean total cost and out-of-pocket cost requirements for infliximab-dyyb and infliximab assuming a standard eight-week dosing regimen. These national means were used to project maximum annual out-of-pocket costs if beneficiaries used each drug and no other prescriptions under a standard 2017 Part D benefit. As part of Part D, beneficiaries receive a discount during the coverage gap for brand-name drugs and biologics but not for biosimilars.

The researchers found that fewer plans covered infliximab-dyyb than infliximab (10 versus 96 percent of the 2,547 plans). The mean total cost per eight-week prescription and annually was modestly lower for infliximab-dyyb ($2,185 versus $2,667 and $14,202 versus $17,335, respectively). For infliximab-dyyb, plans universally required coinsurance cost-sharing; coinsurance rates were similar to infliximab (26.6 versus 28.4 percent of drug cost, respectively). Projected annual out-of-pocket costs were higher for infliximab-dyyb than for infliximab without gap discounts ($5,118 versus $3,432).

"Although biosimilar gap discounts begin in 2019, infliximab-dyyb may still not significantly reduce Part D beneficiaries' out-of-pocket costs given its high price and coinsurance cost-sharing similar to infliximab," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Wait Times Have Improved in VA Health Care System

Wait Times Have Improved in VA Health Care ...

Wait times similar to private sector in 2014 but shorter overall and in some specialties in 2017

Medication Treatment for Substance Abuse Up in Facilities

Medication Treatment for Substance Abuse Up in Facilities

2007 to 2016 saw increase in use of medication treatment, reaching 36.1 percent in 2016

Mindfulness, Stress Linked to Menopausal Symptoms

Mindfulness, Stress Linked to Menopausal Symptoms

Link between mindfulness and symptoms more robust in women experiencing higher stress

is free, fast, and customized just for you!




Already a member?

Sign In Now »